Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study will assess minimal residual disease (MRD) in HER2-positive early breast cancer patients in Asian countries. The purpose is to evaluate the relation between the detection rate of MRD and recurrence.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 20 lat lub więcej
- •Potwierdzony rozpoznanie raka piersi HER2-dodatniego
- •Planowana chemioterapia przed operacją, a następnie chirurgia
- •Zaawansowanie nowotworu w stopniu IIA-IIIC
- •Znany status receptorów hormonalnych
- •Podpisana świadoma zgoda na uczestnictwo
✗ Disqualifies
- •Każdy inny nowotwór w ciągu ostatnich 5 lat (z wyjątkiem raka skóry lub zmian przednowotworowych przełyku, żołądka, jelita grubego lub szyjki macicy)
- •Jednoczesny rak piersi obu piersi
- •Historia raka piersi w przeszłości
- •Ciąża w momencie rejestracji
Simplified criteria — AI translation
Trial details
- Minimum age
- 20 Years
- Last updated (source)
- March 25, 2024
- Sex
- No restrictions
Locations (1)
National Cancer Center Hospital, Japan
Chuo-ku, Japan
Trial contact
Yuki Kojima, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.